Dyne Therapeutics, Inc. (DYN) announced key leadership changes on Tuesday. Doug Kerr will assume the role of Chief Medical Officer, succeeding Wildon Farwell.
Chief Operating Officer Susanna High and Chief Business Officer Jonathan McNeill are departing the company to pursue new opportunities.
To ensure continuity in clinical initiatives, Farwell will remain with Dyne Therapeutics full-time through the end of 2024.
Kerr brings over 25 years of clinical development experience, particularly in neurology. Prior to joining Dyne Therapeutics, he served as a Venture Partner at Atlas Venture and Chief Medical Officer at Generation Bio.
Additionally, Johanna Friedl-Naderer, the former Executive VP and COO at Vir Biotechnology, will take on the role of Chief Commercial Officer. Lucia Celona has been appointed as the new Chief Human Resources Officer.
